Cargando…

PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass

PURPOSE: Alendronate is a widely used anti-osteoporotic drug. PFN1 gene is a newly identified early-onset Paget’s disease pathogenic gene. The purpose of this study is to study whether the genetic variations in this gene affect the clinical efficacy of alendronate in postmenopausal Chinese women wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jiao, Liu, Li, Lv, Shanshan, Wang, Chun, Yue, Hua, Zhang, Zhenlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711734/ https://www.ncbi.nlm.nih.gov/pubmed/34992429 http://dx.doi.org/10.2147/PGPM.S344818

Ejemplares similares

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density
por: Yuan, Hu, et al.
Publicado: (2023)

Association between NF-κB Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density
por: Shen, Xiaoyi, et al.
Publicado: (2022)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women
por: Berkhout, J, et al.
Publicado: (2016)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

Associations of Serum Cathepsin K and Polymorphisms in CTSK Gene With Bone Mineral Density and Bone Metabolism Markers in Postmenopausal Chinese Women
por: Gao, Li-hong, et al.
Publicado: (2020)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with PFN1 Mutation Are Treatable by Alendronate
por: Ling, Zhu, et al.
Publicado: (2023)

Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study
por: Grima, Daniel T, et al.
Publicado: (2010)

Association between parity and bone mineral density in postmenopausal women
por: Yang, Yimei, et al.
Publicado: (2022)

Lean Body Mass in the Prediction of Bone Mineral Density in Postmenopausal Women
por: Ilesanmi-Oyelere, Bolaji Lilian, et al.
Publicado: (2018)

Association between age at menarche and bone mineral density in postmenopausal women
por: Yang, Yimei, et al.
Publicado: (2023)

Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial
por: Yoon, Byung-Koo, et al.
Publicado: (2017)

Association of ADIPOR1 polymorphisms with bone mineral density in postmenopausal Korean women
por: Kim, Ha Young, et al.
Publicado: (2012)

Association of chemerin levels and bone mineral density in Chinese obese postmenopausal women
por: Shi, Liang, et al.
Publicado: (2016)

Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis
por: Shi, Zhen-Yu, et al.
Publicado: (2017)

Associations between bone mineral density, trabecular bone score, and body mass index in postmenopausal females
por: Shayganfar, Azin, et al.
Publicado: (2020)

Contributions of lean mass and fat mass to bone mineral density: a study in postmenopausal women
por: Ho-Pham, Lan T, et al.
Publicado: (2010)

Effect of fat mass and lean mass on bone mineral density in postmenopausal and perimenopausal Thai women
por: Namwongprom, Sirianong, et al.
Publicado: (2013)

Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2005)

Influence of the appendicular skeletal muscle mass index on the bone mineral density of postmenopausal women
por: da Cruz, Geise Ferreira, et al.
Publicado: (2021)

Lean mass as a determinant of bone mineral density of proximal femur in postmenopausal women
por: Marin-Mio, Rosangela Villa, et al.
Publicado: (2018)

Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2008)

Association of chemerin levels and bone mineral density in Chinese obese postmenopausal women: Erratum
Publicado: (2016)

Association between renal function and bone mineral density in healthy postmenopausal Chinese women
por: Li, Shuang, et al.
Publicado: (2019)

ALOX12 polymorphisms are associated with fat mass but not peak bone mineral density in Chinese nuclear families
por: Xiao, W-J, et al.
Publicado: (2011)

Association of Severity of Coronary Lesions with Bone Mineral Density in Postmenopausal Women
por: Xu, Rui, et al.
Publicado: (2018)

Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women
por: Chen, Yusi, et al.
Publicado: (2016)

Spine trabecular bone scores and bone mineral density of postmenopausal Taiwanese women
por: Huang, Mei-Lan, et al.
Publicado: (2022)

Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia
por: Liang, Ying, et al.
Publicado: (2016)

Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis
por: Horst-Sikorska, Wanda, et al.
Publicado: (2012)

Establishing Reference Intervals for Bone Turnover Markers in the Healthy Shanghai Population and the Relationship with Bone Mineral Density in Postmenopausal Women
por: Hu, Wei-Wei, et al.
Publicado: (2013)

Effect of Childbirth Age on Bone Mineral Density in Postmenopausal Women
por: We, Ji Sun, et al.
Publicado: (2018)

Association between fibrinogen and bone mineral density in postmenopausal women
por: Du, Weibin, et al.
Publicado: (2023)

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors
por: Asaoka, Daisuke, et al.
Publicado: (2016)

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
por: Jensen, Paw, et al.
Publicado: (2022)

Genetic Polymorphisms of Nuclear Factor-κB Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women
por: Wang, Wen-Jie, et al.
Publicado: (2022)

Regulatory SNP of RREB1 is Associated With Bone Mineral Density in Chinese Postmenopausal Osteoporosis Patients
por: Feng, Shuo, et al.
Publicado: (2021)

Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women
por: Jordan, Natasha, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_b3laboms4emqjqo5o1oau2c7he